| DC12407 |
Class I and IIB HDAC inhibitor 42 |
Class I and IIB HDAC inhibitor 42 is a novel potent, selective class I and IIB inhibitor (HDAC1 Ki=0.27 nM) for topical treatment of cutaneous t-cell lymphoma.. |
|
| DCAPI1085 |
Clevudine (Levovir)
Featured
|
Clevudine (Levovir) is an antiviral drug for the treatment of hepatitis B,showed potent activity against COVID-19(SARS-COV-2) . |
|
| DCAPI1113 |
Clindamycin HCl (Dalacin) |
Clindamycin HCl (Dalacin) |
|
| DCAPI1131 |
Clindamycin phosphate |
Clindamycin phosphate |
|
| DC10204 |
Clinofibrate |
Clinofibrate (S-8527) is a hypelipidemic agent and a HMG-CoA reductase inhibitor. |
|
| DC10242 |
5-Chloro-8-hydroxy-7-iodoquinoline |
Clioquinol is an orally bioavailable, lipophilic, copper-binding, halogenated 8-hydroxyquinoline with antifungal, antiparasitic and potential antitumor activities. |
|
| DC21722 |
CLK-IN-T3
Featured
|
CLK inhibitor T3 (T3) is a highly potent, selective, and cell-based stable CDC-like kinase (CLK) inhibitor with 0.67, 15 and 110 nM for CLK1,2 and 3, respectively. |
|
| DC23464 |
Clobenpropit |
Clobenpropit (VUF-9153) is a highly potent histamine H3 antagonist/inverse agonist with pA2 value of 9.93, also displays partial agonist activity at H4 receptors. |
|
| DC23440 |
Clobenpropit dihydrobromide |
Clobenpropit (VUF-9153) is a highly potent histamine H3 antagonist/inverse agonist with pA2 value of 9.93, also displays partial agonist activity at H4 receptors. |
|
| DCAPI1133 |
Clobetasol propionate |
Clobetasol propionate |
|
| DC12304 |
Clocapramine hydrochloride hydrate (3-Chlorocarpipramine hydrochloride hydrate) |
Clocapramine hydrochloride hydrate is an antagonist of the D2 and 5-HT2A receptors. |
|
| DCAPI1428 |
Clofarabine
Featured
|
Clofarabine(Clolar; Clofarex) inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase. IC50 Value: 65 nM Target: in vitro: Clofarabine is a second generation purine nucleoside analog with antineoplastic activity. It |
|
| DC9156 |
Clofazimine |
Clofazimine is a fat-soluble iminophenazine dye, has a marked anti-inflammatory effect, has been used in combination with other antimycobacterial drugs to treat AIDS and Crohn's disease. |
|
| DC8681 |
Clofentezine |
Clofentezine, a growth inhibitor, has sublethal effects on life-table parameters of Tetranychus urticae Koch females. |
|
| DC9081 |
Clomipramine HCL |
Clomipramine HCl is a serotonin transporter (SERT), norepinephrine transporter (NET) dopamine transporter (DAT) blocker with Ki of 0.14, 54 and 3 nM, respectively. |
|
| DC9021 |
Clonidine hydrochloride |
Clonidine Hydrochloride is a centrally acting alpha-agonist hypotensive agent. |
|
| DC8672 |
Cloquintocet-mexyl |
Cloquintocet-mexyl is a herbicide, used to control coarse annual grass of the family poaceae (gramineae). |
|
| DC12714 |
CLP-290
Featured
|
CLP290 (CLP-290) is an orally acirtve small molecule K+-Cl- cotransporter isotype 2 (KCC2) activator, the carbamate prodrug of CLP257; In vivo co-treatment with morphine and oral CLP290 prevented membrane KCC2 downregulation in SDH neurons. Concurrently, co-treatment with CLP290 significantly mitigated MIH and acute administration of CLP257 in established MIH restored normal nociceptive behavior. |
|
| DC9797 |
18-[4-(2,2-Difluoro-3-aza-1-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-1(12),4,6,8,10-pentaen-8-yl)phenyl]octadecyl-[2-(trimethylazaniumyl)ethoxy]phosphinate
Featured
|
CLR1501 is a synthetic analogs of the tumor-targeting agent alkylphosphocholine (APC), which is specifically attracted to cancer cells. |
|
| DC11067 |
CLSP37 |
CLSP37 (RIPK2 inhibitor CLSP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling. |
|
| DC11068 |
CLSP43 |
CLSP43 (RIPK2 inhibitor CLSP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling. |
|
| DC21063 |
CM03 |
CM03 is a G-quadruplex-binding compound that potently inhibits cell growth in PDAC cell lines (MIA PaCa-2 IC50=19 nM). |
|
| DC7605 |
CM346(Afobazole)
Featured
|
CM-346 increased the power of the low-frequency θ-rhythm (4.8–5.8 Hz) and the dominant activity peak (6.0–7.2 Hz) and decreased the spectral power in the 19–20 Hz band. |
|
| DC12629 |
CM-675 |
CM-675 (CM675) is a potent, dual PDE5 and classI-HDAC inhibitor with IC50 of 114/673 nM for PDE5A/HDAC1, respectively. |
|
| DC20913 |
CMA-008 |
CMA-008 is a cell-permeable, small molecule modulator of NAADP-mediated Ca2+ release, competes with NAADP binding, inhibit Ca2+ release via the NAADP receptor (IC50=15 uM-1 mM). |
|
| DCAPI1542 |
CMC·HCI |
CMC·HCI |
|
| DC23813 |
CMC2.24 |
CMC2.24 (TRB-N0224) is a novel tricarbonylmethane agent that inhibits the Ras-RAF-MEK-ERK pathway, inhibits Ras activation in pancreatic cancer both in vitro and in vivo. |
|
| DC7388 |
c-Met inhibitor 1 |
c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer. |
|
| DC21530 |
CMP-5
Featured
|
CMP-5 (PRMT5-IN-5) is a first-in-class, small-molecule inhibitor that specifically targets protein arginine methyltransferase 5 (PRMT5), an enzyme involved in epigenetic regulation and cellular signaling. PRMT5 catalyzes the symmetric dimethylation of arginine residues on histones and other proteins, playing a critical role in gene expression, cell proliferation, and survival. CMP-5 has shown remarkable specificity in blocking Epstein-Barr virus (EBV)-driven B-lymphocyte transformation and survival, while sparing normal B cells, making it a promising therapeutic candidate for EBV-associated cancers and other PRMT5-dependent diseases. |
|
| DC21531 |
CMP-5 hydrochloride |
CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells. |
|
